Craft
Poxel

Poxel

Revenue

€13.4 M

FY, 2021

Market Capitalization

€42.3 M

2022-11-18

Poxel Summary

Company summary

Overview
Poxel, a research integrated pharmaceutical company, engages in developing products for metabolic diseases with a focus on Type 2 diabetes. It offers Imeglimin, an orally active adjunct for diet and exercises to improve glycemic control in patients with type 2 diabetes; Glucagon-like peptide-1 receptor agonist, an incretin hormone displaying glucose-dependent stimulation of insulin secretion and restoring the normal profile of insulin release in response to glucose; and AMP-activated protein kinase activator, an enzyme that controls whole-body energy metabolism by regulating glucose and fatty acid homeostasis in various peripheral tissues, such as skeletal muscle and liver. 
Type
Public
Status
Active
Founded
2009
HQ
Lyon, FR | view all locations
Website
https://www.poxelpharma.com/
Cybersecurity rating
Sectors

Key people

  • Thomas Kuhn

    Thomas Kuhn, Chief Executive Officer, Co-Founder, Director

  • Anne Renevot

    Anne Renevot, Executive Vice President, Chief Financial Officer

  • Noah D. Beerman

    Noah D. Beerman, Executive Vice President, Business Development and President, U.S. Operations

    • Richard Kender

      Richard Kender, Independent Director

      LocationsView all

      3 locations detected

      • Lyon, Auvergne-Rhône-Alpes HQ

        France

        259 Avenue Jean Jaurès

      • Cambridge, MA

        United States

        One Broadway, 1 Broadway 14th Floor

      • Chiyoda City, Tokyo

        Japan

      Poxel Financials

      Summary financials

      Revenue (H1, 2022)
      €83.0K
      Gross profit (H1, 2022)
      €939.0K
      Net income (H1, 2022)
      (€13.4M)
      Cash (H1, 2022)
      €16.1M
      EBIT (H1, 2022)
      (€12.2M)
      Enterprise value
      $60.2M

      Footer menu